Page 3 - Ocular Presentation News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Putting Australian clinical research on the map globally, comes the ground-breaking first-in-human clinical trial for KIO-301. MELBOURNE, Australia, Feb. 15, 2023 /PRNewswire/ -- In collaboration with US-based Kiora Pharmaceuticals, Inc. (NASDAQ: KPRX) and The Royal Adelaide Hospital, leading Australian CRO, Accelagen, is proud to announce that dosing has commenced in the Phase 1 first-in-human trial for KIO-301. This trial represents a remarkable development in the treatment of people with the rare inherited condition, Retinitis Pigmentosa (RP), which currently has no approved cure or standar...

/PRNewswire/ -- In collaboration with US-based Kiora Pharmaceuticals, Inc. (NASDAQ: KPRX) and The Royal Adelaide Hospital, leading Australian CRO, Accelagen,...

U.S. stocks traded mostly lower this morning, with the Dow Jones dropping over 150 points on Tuesday. The Dow traded down 0.46% to 33,779.00 whil...

Encinitas, California--(Newsfile Corp. - February 7, 2023) - Kiora Pharmaceuticals, Inc. (NASDAQ: KPRX), ("Kiora" or the "Company") today announced it has received investigational new drug application

Encinitas, California--(Newsfile Corp. - February 3, 2023) - Kiora Pharmaceuticals, Inc. (NASDAQ: KPRX) ("Kiora" or the "Company") today announced that it has entered into a common stock purchase agreement